Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes Journal Article


Authors: Zeidan, A. M.; Lee, J. W.; Prebet, T.; Greenberg, P.; Sun, Z.; Juckett, M.; Smith, M. R.; Paietta, E.; Gabrilove, J.; Erba, H. P.; Tallman, M. S.; Gore, S. D.
Article Title: Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
Abstract: Summary: The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients. © 2014 John Wiley & Sons Ltd.
Keywords: prognostic models; azacitidine; myelodysplastic syndromes; french prognostic scoring system; revised international prognostic scoring system
Journal Title: British Journal of Haematology
Volume: 166
Issue: 3
ISSN: 0007-1048
Publisher: John Wiley & Sons  
Date Published: 2014-08-01
Start Page: 352
End Page: 359
Language: English
DOI: 10.1111/bjh.12884
PROVIDER: scopus
PUBMED: 24712482
PMCID: PMC4299460
DOI/URL:
Notes: Export Date: 1 August 2014 -- CODEN: BJHEA -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Martin Stuart Tallman
    649 Tallman